We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Bioprosthetic Heart Valve Demonstrates Long-Term Durability

By HospiMedica International staff writers
Posted on 23 Mar 2011
The Mosaic bioprosthetic heart valve has demonstrated positive performance results at 12 years, according to a long-term study. More...


Researchers at the University of British Columbia (UBC; Vancouver, Canada) conducted a study that evaluated 1,029 patients who received the Medtronic Mosaic porcine bioprostheses between 1994 and 2000, including 797 patients (mean age of 69 years) who had aortic valve replacement (AVR) and 232 patients (mean age of 67) who had mitral valve replacement (MVR). The predominant area of interest in the study was the durability of the prosthesis in the MVR position.

The results of the study revealed a freedom from structural valve deterioration of 93.3% of AVR patients 60 years and older, and in 95.3% of MVR patients 70 years and older. In addition, hemodynamic performance data showed stability up to 10 years, indicating durability of the bioprosthesis itself over time. The Mosaic bioprosthetic heart valve, a product of Medtronic (Minneapolis, MN, USA), is an artificial heart valve made of porcine tissue that is attached to a cloth-covered, flexible plastic stent, designed with advanced technology for tissue preservation and calcium mitigation. The study was published in the March 2011 issue of the Journal of Thoracic and Cardiovascular Surgery.

"These strong findings address and support the intermediate- to long-term durability of the Medtronic Mosaic bioprosthesis in the aortic and mitral position,” said lead author Professor Eric Jamieson, MD, of the UBC department of surgery. "Until now, there has been limited published documentation of the durability of this newer generation of bioprosthesis. I expect these results will be reviewed favorably by cardiothoracic surgeons, especially for patients 60 years of age and older requiring aortic valve replacement and patients 70 years of age and older who are candidates for mitral valve replacement.”

Related Links:

University of British Columbia
Medtronic



Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Anesthetic Gas Measurement Module
Scio Four
New
Mattress System
Apollo Infant Dynamic
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.